Slingshot members are tracking this event:
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission approval for BENEPALI, an etanercept biosimilar referencing Enbrel
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jan 16, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Joint Venture, European Commission Approval, Ec, Etanercept, Biosimilar, Enbrel, Severe Rheumatoid Arthritis, Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, Plaque Psoriasis, Subcutaneous Anti-tnf Biosimilar, Chronic Inflammatory Conditions